Study of detergent-mediated liberation of hepatitis B virus-like particles from S. cerevisiae homogenate: identifying a framework for the design of future-generation lipoprotein vaccine processes.
Virus-like particles (VLPs) are expressed intracellularly in Saccharomyces cerevisiae and the recovery process involves the use of a detergent, which facilitates the release of VLP from host cell components. The detergent-mediated liberation of VLPs is a critical step in primary recovery and is responsible for setting the backdrop for subsequent purification in terms of product yield and characteristics of the process stream. In this paper the use of Triton X-100 detergent for the recovery of lipid envelope VLPs, using the hepatitis B surface antigen (HBsAg) as the VLP model, was investigated. To develop a framework that can be adopted in process design for future generation VLP vaccine candidates, the impact of Triton X-100 was characterized via different response factors: (i) recovery and activity of the HBsAg; (ii) level of protein and lipid contamination from the host cell; and (iii) indirect impact on the performance of an ultrafiltration step following primary recovery. Our studies identified that an increase in detergent concentration favors recovery of HBsAg only to a specific threshold, 0.5% v/v Triton X-100. Further increase in detergent results in delipidation of HBsAg leading to loss in antigenic activity. The level of contamination due to host protein and lipid co-liberation is in proportion with the amount of detergent employed. Greater membrane resistance during ultrafiltration was observed for samples generated using higher concentrations of detergent due to the increase in membrane fouling by the contaminants. Based on this study, Triton X-100 concentrations in the range of 0.2-0.5% v/v appears to be most suitable for recovery of native HBsAg. Choosing between 0.2-0.5% v/v would involve identifying a suitable tradeoff between desired product yield and the level of contamination that can be tolerated by downstream operations.
Kee
Gaik Sui
GS
The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, UK.
Pujar
Narahari S
NS
Titchener-Hooker
Nigel J
NJ
D005591:Chemical Fractionation / Q000379:methods; D003902:Detergents / Q000737:chemistry*; D004655:Emulsions / Q000302:isolation & purification; D006509:Hepatitis B / Q000378:metabolism*; D017325:Hepatitis B Vaccines / Q000302:isolation & purification*; D008074:Lipoproteins / Q000302:isolation & purification / Q000627:therapeutic use; D017830:Octoxynol / Q000737:chemistry*; D012441:Saccharomyces cerevisiae / Q000737:chemistry* / Q000821:virology*; D014462:Ultrafiltration / Q000379:methods; D014771:Virion / Q000302:isolation & purification*
D003902:Detergents; D004655:Emulsions; D017325:Hepatitis B Vaccines; D008074:Lipoproteins; D017830:Octoxynol